Progress in pancreatic cancer therapeutics: The potential to exploit molecular targets

Table 2 Phase III trials with targeted treatment in metastatic pancreatic cancer

Date published	Regimen	Ref.	Sample size (n)	Median OS (mo)	P value
2001	Gem vs Gem + 5FU	Berlin et al[103]	322	5.4	0.09
				6.7
2004	Gem vs Gem + Irinotecan	Rocha Lima et al[104]	360	6.6	0.789
				6.3
2005	Gem vs GemOx	Louvet et al[105]	326	7.1	0.13
				9.0
2007	Gem vs Gem + cape	Herrmann et al[106]	319	7.2	0.234
				8.4
2006	Gem vs Gem + Irinotecan	Stathopoulos et al[107]	145	6.4	0.970
				6.5
2006	Gem vs Gem + Cisplatin	Heinemann et al[108]	195	6.0	0.15
				7.5

Gem: Gemcitabine; 5FU: 5-Fluoruracil; GemOx: Gemcitabine + Oxaliplatin; cape: Capecitabine.